T0	KEYPHRASE_NOTYPES 62 80	antibiotic therapy
T1	KEYPHRASE_NOTYPES 108 123	Lyme arthritis.
T2	KEYPHRASE_NOTYPES 201 218	oral antibiotics,
T3	KEYPHRASE_NOTYPES 233 256	oral antibiotic regimen
T4	KEYPHRASE_NOTYPES 380 397	oral antibiotics,
T5	KEYPHRASE_NOTYPES 412 427	IV ceftriaxone,
T6	KEYPHRASE_NOTYPES 645 804	IV oral
T7	KEYPHRASE_NOTYPES 906 917	IV therapy.
T8	KEYPHRASE_NOTYPES 947 963	persistent joint
T9	KEYPHRASE_NOTYPES 1014 1024	IV therapy
T10	KEYPHRASE_NOTYPES 1072 1099	synovial tissue hypertrophy
T11	KEYPHRASE_NOTYPES 1152 1166	IV antibiotics
T12	KEYPHRASE_NOTYPES 1392 1427	additional oral amoxicillin therapy
T13	KEYPHRASE_NOTYPES 1453 1468	IV ceftriaxone.
T14	KEYPHRASE_NOTYPES 1492 1508	oral antibiotics
T15	KEYPHRASE_NOTYPES 1515 1575	FDA daptomycin, carbomycin,
T16	KEYPHRASE_NOTYPES 1580 1593	cefoperazone,
T17	KEYPHRASE_NOTYPES 1625 1633	efficacy
T18	KEYPHRASE_NOTYPES 1653 1664	spirochetes
T19	KEYPHRASE_NOTYPES 1767 1781	Lyme arthritis
